Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $27.9 million.

  • Janux Therapeutics' Non-Current Assets fell 7.03% to $26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.7 million, marking a year-over-year decrease of 7.03%. This contributed to the annual value of $27.9 million for FY2024, which is 10.64% down from last year.
  • As of FY2024, Janux Therapeutics' Non-Current Assets stood at $27.9 million, which was down 10.64% from $31.2 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Non-Current Assets ranged from a high of $31.6 million in FY2022 and a low of $155,000 during FY2020.
  • Moreover, its 3-year median value for Non-Current Assets was $31.2 million (2023), whereas its average is $30.2 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 1,709.68% in 2021, then fell by 10.64% in 2024.
  • Yearly analysis of 5 years shows Janux Therapeutics' Non-Current Assets stood at $155,000 in 2020, then soared by 1,709.68% to $2.8 million in 2021, then skyrocketed by 1,025.53% to $31.6 million in 2022, then dropped by 1.28% to $31.2 million in 2023, then declined by 10.64% to $27.9 million in 2024.